Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state.
Laura A BosmansClaudia M van TielSuzanne A B M AartsLisa WillemsenJeroen BaardmanBram W van OsMyrthe den ToomLinda BeckersDavid J AhernJohannes H M LevelsAldo JongejanPerry D MoerlandSanne G S VerberkJan Van den BosscheMenno M P J de WintherChristian WeberDorothee AtzlerClaudia MonacoNorbert GerdesAnnelie ShamiEsther LutgensPublished in: Cardiovascular research (2022)
We here show that absence of CD40 signalling in myeloid cells reduces atherosclerosis and limits systemic inflammation by preventing a shift in macrophage polarization towards pro-inflammatory states. Our study confirms the merit of macrophage-targeted inhibition of CD40 as a valuable therapeutic strategy to combat atherosclerosis.